List view / Grid view
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor...
6 July 2016 | By Victoria White, Digital Content Producer
Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform...
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
2 June 2015 | By Victoria White
Encouraging results have been announced from a Phase 1/2 trial of SCIB1, a DNA ImmunoBody being developed for the treatment of patients with melanoma...
